ArticlePediatric cardiology2026
Application of the New 2023 World Heart Federation Criteria to Rheumatic Heart Disease in the Setting of First Episode of Acute Rheumatic Fever: Predictors for Resolution.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictors of Resolution in Rheumatic Heart Disease: Application of the 2023 WHF Criteria in First-Episode Acute Rheumatic Fever.Pediatric cardiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Rheumatic heart disease (RHD) is a chronic complication of acute rhematic fever (ARF). Echocardiography is used to assess valve disease in ARF. Acute valvulitis in ARF may normalise once inflammation has subsided. In the Top End of the Northern Territory (NT), a diagnosis of RHD is regularly made in conjunction with ARF diagnosis. We aimed to determine if baseline echocardiogram features could predict resolution of RHD when diagnosed during ARF. This retrospective cohort study includes children and young Australians diagnosed concurrently with first ARF and RHD between January 2012 and December 2021. Echocardiograms were reclassified based on the 2023 World Heart Federation guidelines for diagnosis of RHD. Primary outcome was echocardiographic resolution of RHD. The NT register recorded 311 individuals with concurrent diagnoses of ARF and RHD with 165 eligible for inclusion. Median age was 10 years (IQR 8-13 years), and 51.5% were female. Early RHD was diagnosed in 64% (106/165) of cases. Median follow-up time was 34 months. Resolution of RHD occurred in 19% (32/165) and 97% (31/32) of those had Early RHD at diagnosis. Absence of mitral valve leaflet thickening, restriction, and excessive leaflet motion were all associated with RHD resolution with univariate analysis. Multivariate Cox proportional modelling found that Early RHD at baseline independently predicted RHD resolution with HR of 16.6 (95% CI 2.25-122.74, p = 0.006). No difference was found between Stage A or Stage B RHD, (p = 0.461). The morphological features of valve disease were not as important as the severity in predicting resolution of RHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.